Semaglutide use before atrial fibrillation ablation reduces recurrent arrhythmia risk in focused meta-analysis

Atrial fibrillation (AF) is the most common sustained arrhythmia, significantly increasing stroke risk and mortality. Catheter ablation is an effective treatment, but recurrence rates remain high, especially in patients with comorbidities like obesity. Weight loss is known to improve AF outcomes, yet current weight management strategies often fall short. GLP-1 receptor agonists like semaglutide offer potent weight reduction and cardiovascular benefits, making them a promising adjunct therapy to optimize outcomes post-ablation by addressing underlying risk factors and improving overall cardiac health.

This focused time-to-event meta-analysis systematically reviewed existing literature to assess the impact of semaglutide on recurrent arrhythmia in patients undergoing atrial fibrillation ablation. Researchers conducted a comprehensive search of databases for studies reporting on semaglutide use in this specific patient population. The primary endpoint was time to recurrent arrhythmia post-ablation. Statistical methods appropriate for time-to-event data, such as hazard ratios and Kaplan-Meier analyses, were employed to synthesize findings across included studies and evaluate the overall effect.

This meta-analysis aimed to quantify the association between semaglutide use and the risk of recurrent atrial fibrillation or other arrhythmias following catheter ablation. While specific numerical findings, such as hazard ratios, p-values, or percentage reductions in recurrence, are not provided in the source abstract, the study's objective was to determine if semaglutide significantly prolonged the time to arrhythmia recurrence. The methodology focused on aggregating time-to-event data from various studies to provide a robust estimate of effect.

The meta-analysis sought to establish whether semaglutide could improve long-term rhythm outcomes by reducing the incidence or delaying the onset of post-ablation arrhythmias. The findings would typically include pooled estimates of effect size, confidence intervals, and assessments of heterogeneity among studies to understand the consistency of the observed effects across different populations and study designs.